Earnings ·
On August 12, 2026, Monopar Therapeutics Inc. reported financial results for the second quarter ended June 30, 2026…
MNPRMonopar Therapeutics
On August 12, 2026, Monopar Therapeutics Inc. reported financial results for the second quarter ended June 30, 2026, and announced it initiated a rolling New Drug Application (NDA) submission to the FDA on July 22, 2026, for ALXN1840, its first-in-class treatment for Wilson disease. The company reported a net loss of $5.3 million ($0.62 per share), compared to a $2.5 million loss in the prior year period, with cash and investments totaling $134.3 million sufficient to fund operations through at least December 31, 2027. R&D expenses increased to approximately $4.8 million due to higher contractor and personnel costs, while General and Administrative expenses rose to roughly $1.9 million. The filing also highlighted the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer and board member Nicole Sweeny to support commercial launch preparations for ALXN1840. Monopar Therapeutics is a clinical-stage biopharmaceutical company developing innovative treatments for Wilson disease and advanced cancers.